Compare Virgin Galactic Holdings, Inc. (SPCE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs GeneDx Holdings Corp — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.97 (market cap $445.69M), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 4.5× Virgin Galactic Holdings, Inc.'s market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 5,128,850). Which is the better fit depends on your goals — on Pluang, investors hold Virgin Galactic Holdings, Inc. for 69 Days and GeneDx Holdings Corp for 19 Days on average.
| SPCE | WGS | |
|---|---|---|
Market Cap | $445.69M | $2.02B |
Volume | 5,128,850 | 734,640 |
Sector | Industrials | Health |
52-Week High | $7.52 | $167.51 |
52-Week Low | $2.17 | $34.51 |
Typical Hold Time | 69 Days | 19 Days |
Enterprise Value | $409.68M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting ongoing investor skepticism despite recent earnings beats. The company continues to burn cash with negative operating cash flow of $240.14 million in 2025 and deeply negative profit margins. Technical indicators show a bearish trend with the stock trading near key support levels. Recent news highlights management's guidance for positive cash flow by 2027 but also a delay in commercial Delta flights to February 2027.
The outlook remains highly speculative with significant execution risk. While strong ticket demand provides a potential catalyst, the path to profitability is long and dependent on successful commercial spaceflight operations. Investors face substantial dilution risk and high volatility in this pre-revenue growth phase. The stock represents a high-risk, high-reward opportunity suitable only for risk-tolerant investors.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
